AIM: A validation study was conducted to evaluate the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). This module was designed to assess disease and treatment specific aspects of the quality of life (QoL) of patients with endometrial cancer. METHODS: Two hundred and sixty-eight women with endometrial cancer were recruited in different phases of treatment: after pelvic surgery (Group 1); during adjuvant chemotherapy and/or radiotherapy (Group 2); after completion of treatment (Group 3). Patients completed the EORTC QLQ-C30, the endometrial cancer module and a short debriefing questionnaire. RESULTS: Multi-trait scaling analyses confirmed the hypothesised scale structure of the QLQ-EN24. Internal consistency reliability was good with Cronbach's alpha coefficients ranging from 0.74 to 0.86 (lymphoedema 0.80, urological symptoms 0.75, gastrointestinal symptoms 0.74, body image problems 0.86 and sexual/vaginal problems 0.86). Convergent and discriminant validity did not show any scaling errors for the subscales. The QLQ-EN24 module discriminated well between clinically different groups of patients. All items exhibited a high completion rate with less than 2% missing values except for the sexuality items (19%). CONCLUSION: The validation study supports the reliability, the convergent and divergent validity of the EORTC QLQ-EN24. This newly developed QLQ-EN24 module is a useful instrument for the assessment of the QoL in patients treated for endometrial cancer in clinical trials.
AIM: A validation study was conducted to evaluate the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). This module was designed to assess disease and treatment specific aspects of the quality of life (QoL) of patients with endometrial cancer. METHODS: Two hundred and sixty-eight women with endometrial cancer were recruited in different phases of treatment: after pelvic surgery (Group 1); during adjuvant chemotherapy and/or radiotherapy (Group 2); after completion of treatment (Group 3). Patients completed the EORTC QLQ-C30, the endometrial cancer module and a short debriefing questionnaire. RESULTS: Multi-trait scaling analyses confirmed the hypothesised scale structure of the QLQ-EN24. Internal consistency reliability was good with Cronbach's alpha coefficients ranging from 0.74 to 0.86 (lymphoedema 0.80, urological symptoms 0.75, gastrointestinal symptoms 0.74, body image problems 0.86 and sexual/vaginal problems 0.86). Convergent and discriminant validity did not show any scaling errors for the subscales. The QLQ-EN24 module discriminated well between clinically different groups of patients. All items exhibited a high completion rate with less than 2% missing values except for the sexuality items (19%). CONCLUSION: The validation study supports the reliability, the convergent and divergent validity of the EORTC QLQ-EN24. This newly developed QLQ-EN24 module is a useful instrument for the assessment of the QoL in patients treated for endometrial cancer in clinical trials.
Authors: Mette Moustgaard Jeppesen; Nicole P M Ezendam; Johanna M A Pijnenborg; M Caroline Vos; Dorry Boll; Roy F P M Kruitwagen; Pernille Tine Jensen; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2017-09-05 Impact factor: 4.442
Authors: Amelia M Jernigan; Kathryn A Maurer; Karen Cooper; Philip R Schauer; Peter G Rose; Chad M Michener Journal: Am J Obstet Gynecol Date: 2015-05-14 Impact factor: 8.661
Authors: Mario M Leitao; Qin C Zhou; Natalia R Gomez-Hidalgo; Alexia Iasonos; Ray Baser; Marissa Mezzancello; Kaity Chang; Jae Ward; Dennis S Chi; Kara Long Roche; Yukio Sonoda; Carol L Brown; Jennifer J Mueller; Ginger J Gardner; Elizabeth L Jewell; Vance Broach; Oliver Zivanovic; Sean C Dowdy; Andrea Mariani; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2019-11-25 Impact factor: 5.482
Authors: Lonneke V van de Poll-Franse; Kim A H Nicolaije; Maria C Vos; Johanna M A Pijnenborg; Dorry Boll; Olga Husson; Nicole P M Ezendam; Erik A Boss; Ralph H M Hermans; Karin C M Engelhart; Joke E Haartsen; Brenda M Pijlman; Harrie W H Feijen; Helena J M M Mertens; Willem E Nolting; Johannes J van Beek; Jan A Roukema; Roy F P M Kruitwagen Journal: Trials Date: 2011-12-05 Impact factor: 2.279
Authors: Marieke van Leeuwen; Olga Husson; Paola Alberti; Juan Ignacio Arraras; Olivier L Chinot; Anna Costantini; Anne-Sophie Darlington; Linda Dirven; Martin Eichler; Eva B Hammerlid; Bernhard Holzner; Colin D Johnson; Meropi Kontogianni; Trille Kristina Kjær; Ofir Morag; Sandra Nolte; Andrew Nordin; Andrea Pace; Monica Pinto; Katja Polz; John Ramage; Jaap C Reijneveld; Samantha Serpentini; Krzysztof A Tomaszewski; Vassilios Vassiliou; Irma M Verdonck-de Leeuw; Ingvild Vistad; Teresa E Young; Neil K Aaronson; Lonneke V van de Poll-Franse Journal: Health Qual Life Outcomes Date: 2018-06-04 Impact factor: 3.186
Authors: Maciej Stukan; Kamil Zalewski; Jacek P Grabowski; Marcin Mardas; Steven Jones; Małgorzata Pietrzak-Stukan; Mirosław Dudziak Journal: Contemp Oncol (Pozn) Date: 2014-03-20